1️⃣ Full-Life raised around the isotope bottleneck Full-Life Technologies raised $150 million, split between $110 million of Series D equity and $40 million of debt, to advance 225Ac-FL-020, 225Ac-FL-261 and a Belgium GMP actinium-225 facility.
💡 Why it matters Radiopharma investing is now as much about supply control as asset biology. Owning actinium-225 capacity may de-risk the pipeline before efficacy does.
☕ Coffee talk If actinium is the choke point, who owns enough isotope to scale?
2️⃣ Quince bought itself a pulmonary reset Quince acquired Orphai and lined up up to $187 million in private placement financing around LAM-001, after Phase 2a PH-ILD data showed a 67.4-metre 6MWD gain and a 33.9% PVR reduction in four evaluable patients at 24 weeks.
💡 Why it matters This is a full pivot: asset, financing and clinical story in one move. The data are small, but the runway now points to Phase 2b rather than survival mode.
☕ Coffee talk How much of this rerating is LAM-001, and how much is relief that Quince has a new story?
3️⃣ Accro put RIPK2 on a US clock Accro Bioscience closed a $50 million Series C led by OrbiMed to fund AC-101, its oral RIPK2 inhibitor, through Phase IIb in ulcerative colitis after earlier studies in Australia and China.
💡 Why it matters China-origin I&I is moving from local proof-of-concept into US-ready mid-stage assets. The next question is whether the signal travels.
☕ Coffee talk Is this a UC drug, or another test of how much US investors trust China POC?